Adi Diab
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 113
- Cancer Immunotherapy and Biomarkers 97
- CAR-T cell therapy research 42
- Colorectal Cancer Treatments and Studies 11
- Cutaneous Melanoma Detection and Management 10
- Immunology 54
- Immunotherapy and Immune Responses 37
- Immune Cell Function and Interaction 21
- Co-authors
- Noha Abdel‐Wahab (14 shared papers)Maria Eugenia Suarez-Almazor (8 shared papers)Daniel Hartman Johnson (11 shared papers)Van Anh Trinh (6 shared papers)Michael T. Tetzlaff (14 shared papers)Jonathan L. Curry (12 shared papers)Sapna Pradyuman Patel (19 shared papers)Patrick Hwu (16 shared papers)
- Journals
- Annals of Oncology (21 papers)Journal for ImmunoTherapy of Cancer (20 papers)Journal of Clinical Oncology (10 papers)Clinical Cancer Research (8 papers)Journal of Cutaneous Pathology (5 papers)
- Partner nations
- United StatesEgyptAustralia
In The Last Decade
Adi Diab
165 papers receiving 17.9k citations
Adi Diab's Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 11.3k
- Immunology 5.3k
- Biological Psychiatry 241
- Pulmonary and Respiratory Medicine 2.2k
- Molecular Biology 4.6k
Countries citing papers authored by Adi Diab
This map shows the geographic impact of Adi Diab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adi Diab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adi Diab more than expected).
Fields of papers citing papers by Adi Diab
This network shows the impact of papers produced by Adi Diab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adi Diab. The network helps show where Adi Diab may publish in the future.
Co-authors
The 25 scholars most cited alongside Adi Diab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 168 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Hit paper breakdown → | 2017 | 3810 |
| 2 | Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group Hit paper breakdown → | 2017 | 1589 |
| 3 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Hit paper breakdown → | 2016 | 817 |
| 4 | Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response Hit paper breakdown → | 2021 | 716 |
| 5 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance Hit paper breakdown → | 2017 | 701 |
| 6 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Hit paper breakdown → | 2018 | 679 |
| 7 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade Hit paper breakdown → | 2021 | 349 |
| 8 | 2020 | 298 | |
| 9 | 2016 | 280 | |
| 10 | 2014 | 277 | |
| 11 | Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity Hit paper breakdown → | 2022 | 273 |
| 12 | Neoadjuvant relatlimab and nivolumab in resectable melanoma Hit paper breakdown → | 2022 | 258 |
| 13 | 2019 | 234 | |
| 14 | 2018 | 232 | |
| 15 | Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study Hit paper breakdown → | 2020 | 232 |
| 16 | 2019 | 226 | |
| 17 | 2019 | 221 | |
| 18 | 2010 | 220 | |
| 19 | 2020 | 210 | |
| 20 | 2018 | 206 |
About Adi Diab
Adi Diab is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Molecular Biology and Psychiatry and Mental health, having authored 168 papers that have together received 18.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (97 papers), CAR-T cell therapy research (42 papers), Immunotherapy and Immune Responses (37 papers), Immune Cell Function and Interaction (21 papers), Melanoma and MAPK Pathways (19 papers), Brain Metastases and Treatment (14 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cutaneous Melanoma Detection and Management (10 papers). The work is most often cited by research in Oncology (11.3k citations), Immunology (5.3k citations), Biological Psychiatry (241 citations), Pulmonary and Respiratory Medicine (2.2k citations) and Molecular Biology (4.6k citations). Adi Diab has collaborated with scholars based in United States, Egypt and Australia. Frequent co-authors include Noha Abdel‐Wahab, Maria Eugenia Suarez-Almazor, Daniel Hartman Johnson, Van Anh Trinh, Michael T. Tetzlaff, Jonathan L. Curry, Sapna Pradyuman Patel, Patrick Hwu, Chrystia M. Zobniw and Carlos Antonio Torres-Cabala. Their work appears in journals such as Annals of Oncology, Journal for ImmunoTherapy of Cancer, Journal of Clinical Oncology, Clinical Cancer Research and Journal of Cutaneous Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.